S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL

Seufferlein, Thomas; Mayerle, Julia; Bock, S. Allan; Brunner, Thomas; Ettrich, Thomas Jens; Grenacher, Lars; Gress, Thomas M.; Hackert, Thilo; Kestler, Angelika; Sinn, Marianne; Tannapfel, Andrea; Wedding, Ulrich; Uhl, Waldemar

doi:10.1055/a-1856-7346

Cited by 16 publications

(9 citation statements)

References 678 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neben der 2021/2022 überarbeiteten deutschen „S3-Leitlinie zum exokrinen Pankreaskarzinom“ mit adaptierten Empfehlungen zu den zystischen Tumoren 8 , 9 existiert mit der „Europäischen Leitlinie zu zystischen Tumoren des Pankreas“ der International Study Group eine – allgemein gut akzeptierte – evidenzbasierte Leitlinie zum Umgang mit zystischen Pankreasläsionen 10 , welche die Fukuoka-Empfehlungen modernisiert, erweitert und weitgehend abgelöst hat.…”

Section: Aktueller Wissensstandunclassified

See 1 more Smart Citation

How I do it – Radiologische Abklärung zystischer Pankreastumoren

Schaible¹,

Grenacher²

2023

Radiologie up2date

Self Cite

View full text Add to dashboard Cite

Section: Aktueller Wissensstandunclassified

“…Die Endosonografie steht als komplementäre Diagnostik bei Läsionen größer 1 cm oder bei diagnostischer Unsicherheit 8 , 9 gleichwertig zur Verfügung. Ihre Stärken liegen in der Identifizierung der sog.…”

Section: Diagnostischer Algorithmusunclassified

How I do it – Radiologische Abklärung zystischer Pankreastumoren

Schaible¹,

Grenacher²

2023

Radiologie up2date

Self Cite

View full text Add to dashboard Cite

“…A total of 2,579 family members were followed for up to 20 years, of whom 4.5% developed pancreatic cancer or precursor lesions within 5 years [17]. German guidelines reference the CAPS recommendations and stress the importance of genetic counseling in families with familial pancreatic cancer [18].…”

Section: Early Detection In High-risk Populationsmentioning

confidence: 99%

“…If MRI detects a relevant cystic lesion of more than 10 mm, we schedule EUS within 3–6 months to examine for worrisome features not detected by MRI. We follow-up lesion size with MRI according to national guidelines [18]. If features of the lesion change and indicate worrisome behavior, additional EUS is performed.…”

Section: Early Detection In High-risk Populationsmentioning

confidence: 99%

Early Detection of Pancreatic Cancer

Schwingel¹,

Decker²,

Schneider³

et al. 2023

Oncol Res Treat

View full text Add to dashboard Cite

Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is increasingly common. Screening for pancreatic cancer is not well established but might increase the chance of detection in the early stages. Summary: We conducted a literature search to summarize current recommendations and to give an overview of patient groups that may benefit from screening. In the general population, screening is not recommended because the low prevalence of PDAC renders any diagnostic tests non-predictive and because there is no direct evidence that links early diagnosis to improved survival. To date, novel approaches like liquid biopsies and molecular markers are not yet able to improve screening in unselected individuals but offer promising potential. Screening efficiency increases considerably with increasing pre-test probability. Therefore, the best way to improve early diagnosis is identifying high-risk individuals. Key Messages: There are well-defined populations with distinct genetic alterations with an increased risk for pancreatic cancer. Those may be screened with common diagnostic methods. In addition, new-onset diabetes is increasingly recognized as an early symptom, especially in elderly patients with weight loss.

show abstract

“…If there is differential diagnostic evidence for a lesion in the pancreas that would change the procedure such as a suspected metastasis from another malignancy in the history, EUS-guided sampling is indicated [90]. Before deciding on an EUS-guided sampling, one should always consider if and how this would change the further management of the patient.…”

Section: Eus-guided Samplingmentioning

confidence: 99%

Comments on and Illustrations of the EFSUMB CEUS Guidelines: Transabdominal and Endoscopic Ultrasound Features of Intrapancreatic Metastases and the Role of Multiparametric Imaging and EUS-Guided Sampling in Rare Pancreatic Tumors

Möller

Jenssen

Braden

et al. 2023

Cancers

View full text Add to dashboard Cite

A definite pathologic diagnosis of intrapancreatic metastasis is crucial for the management decision, i.e., curative or palliative surgery versus chemotherapy or conservative/palliative therapy. This review focuses on the appearance of intrapancreatic metastases on native and contrast-enhanced transabdominal ultrasound and endoscopic ultrasound. Differences and similarities in relation to the primary tumor, and the differential diagnosis from pancreatic carcinoma and neuroendocrine neoplasms are described. The frequency of intrapancreatic metastases in autopsy studies and surgical resection studies will be discussed. Further emphasis is placed on endoscopic ultrasound-guided sampling to confirm the diagnosis.

show abstract

S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL

Cited by 16 publications

References 678 publications

How I do it – Radiologische Abklärung zystischer Pankreastumoren

How I do it – Radiologische Abklärung zystischer Pankreastumoren

Early Detection of Pancreatic Cancer

Comments on and Illustrations of the EFSUMB CEUS Guidelines: Transabdominal and Endoscopic Ultrasound Features of Intrapancreatic Metastases and the Role of Multiparametric Imaging and EUS-Guided Sampling in Rare Pancreatic Tumors

Contact Info

Product

Resources

About